Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study

BACKGROUND: Ipragliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubules. SGLT2 inhibitors are expected to be effective in patients with insulin resistance and obesity, but it is important to select treatment according to pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med Res
Autors principals: Iemitsu, Kotaro, Iizuka, Takashi, Takihata, Masahiro, Takai, Masahiko, Nakajima, Shigeru, Minami, Nobuaki, Umezawa, Shinichi, Kanamori, Akira, Takeda, Hiroshi, Kawata, Takehiro, Ito, Shogo, Kikuchi, Taisuke, Amemiya, Hikaru, Kaneshiro, Mizuki, Mokubo, Atsuko, Takuma, Tetsuro, Machimura, Hideo, Tanaka, Keiji, Asakura, Taro, Kubota, Akira, Aoyagi, Sachio, Hoshino, Kazuhiko, Ishikawa, Masashi, Obana, Mitsuo, Sasai, Nobuo, Kaneshige, Hideaki, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
Format: Artigo
Idioma:Inglês
Publicat: Elmer Press 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4817576/
https://ncbi.nlm.nih.gov/pubmed/27081422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2492w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars